Literature DB >> 35792919

Antipsychotic utilization patterns in pregnant women with psychotic disorders: a 16-year population-based cohort study.

Jenny Wai Yiu Law1, Joe Kwun Nam Chan1, Corine Sau Man Wong1, Eric Yu Hai Chen1,2, Wing Chung Chang3,4.   

Abstract

Despite growing concern about reproductive safety of antipsychotics, there is a paucity of research specifically assessing prenatal antipsychotic prescribing practices for psychotic disorders. This population-based cohort study identified women aged 15-50 years with diagnosis of psychotic disorders, who delivered their first and singleton child between 2003-2018 in Hong Kong, with an aim to examine temporal trends and predictors of prenatal antipsychotic use as well as antipsychotic utilization patterns before and during pregnancy. Data were retrieved from territory-wide medical-record database of public healthcare services. Of 804 women, 519 (65%) redeemed at least one prescription for antipsychotics during pregnancy. Older age at conception (25-34 years: OR 2.12 [95% CI 1.22-3.67]; 35-50 years: 2.52 [1.38-4.61]; 15-24 years as reference category) and antipsychotic treatment within 12 months pre-pregnancy (24.22 [16.23-36.16]) were significantly associated with prenatal antipsychotic use. Second-generation-antipsychotic (SGA) use during pregnancy increased over 16-year study period, while prenatal first-generation-antipsychotic (FGA) use showed declining trend. Overall antipsychotic and SGA use progressively decreased across pre-pregnancy and trimesters of pregnancy. Further analyses on antipsychotic use trajectories revealed that 87.4% (n = 459) of 529 women receiving antipsychotics in 12-month pre-pregnancy redeemed antipsychotic prescription during pregnancy, and 63.4% (n = 333) continued antipsychotic treatment throughout pregnancy. Only 7.5% of the cohort (n = 60) commenced antipsychotics in pregnancy. This is one of the few studies evaluating real-world prenatal antipsychotic utilization among women with psychotic disorders. Future research delineating risk conferred by illness-related factors and antipsychotic exposure on adverse maternal and fetal outcomes is warranted to facilitate treatment guideline development.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Antipsychotics; Drug utilization; Population-based; Pregnancy; Psychotic disorders

Year:  2022        PMID: 35792919     DOI: 10.1007/s00406-022-01453-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  43 in total

1.  Lifetime prevalence of psychotic and bipolar I disorders in a general population.

Authors:  Jonna Perälä; Jaana Suvisaari; Samuli I Saarni; Kimmo Kuoppasalmi; Erkki Isometsä; Sami Pirkola; Timo Partonen; Annamari Tuulio-Henriksson; Jukka Hintikka; Tuula Kieseppä; Tommi Härkänen; Seppo Koskinen; Jouko Lönnqvist
Journal:  Arch Gen Psychiatry       Date:  2007-01

2.  Antipsychotic Exposure in Pregnancy and the Risk of Gestational Diabetes: A Systematic Review and Meta-analysis.

Authors:  Suat Kucukgoncu; Sinan Guloksuz; Kubra Celik; Mert Ozan Bahtiyar; Jurjen J Luykx; Bart P F Rutten; Cenk Tek
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

3.  Lifetime Prevalence and Correlates of Schizophrenia-Spectrum, Affective, and Other Non-affective Psychotic Disorders in the Chinese Adult Population.

Authors:  Wing Chung Chang; Corine Sau Man Wong; Eric Yu Hai Chen; Linda Chiu Wa Lam; Wai Chi Chan; Roger Man Kin Ng; Se Fong Hung; Eric Fuk Chi Cheung; Pak Chung Sham; Helen Fung Kum Chiu; Ming Lam; Edwin Ho Ming Lee; Tin Po Chiang; Lap Kei Chan; Gary Kar Wai Lau; Allen Ting Chun Lee; Grace Tak Yu Leung; Joey Shuk Yan Leung; Joseph Tak Fai Lau; Jim van Os; Glyn Lewis; Paul Bebbington
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

Review 4.  An update on medication management of women with schizophrenia in pregnancy.

Authors:  Carolyn Breadon; Jayashri Kulkarni
Journal:  Expert Opin Pharmacother       Date:  2019-05-15       Impact factor: 3.889

Review 5.  Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: A systematic review and meta-analysis.

Authors:  Padraig Oakley; Steve Kisely; Amanda Baxter; Meredith Harris; Jocelyne Desoe; Alyona Dziouba; Dan Siskind
Journal:  J Psychiatr Res       Date:  2018-04-26       Impact factor: 4.791

6.  The lifetime risk of suicide in schizophrenia: a reexamination.

Authors:  Brian A Palmer; V Shane Pankratz; John Michael Bostwick
Journal:  Arch Gen Psychiatry       Date:  2005-03

Review 7.  The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

Authors:  Per Damkier; Poul Videbech
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 8.  Schizophrenia during pregnancy.

Authors:  Paola Dazzan
Journal:  Curr Opin Psychiatry       Date:  2021-05-01       Impact factor: 4.787

9.  Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries.

Authors:  Brendon Stubbs; Ai Koyanagi; Nicola Veronese; Davy Vancampfort; Marco Solmi; Fiona Gaughran; André F Carvalho; John Lally; Alex J Mitchell; James Mugisha; Christoph U Correll
Journal:  BMC Med       Date:  2016-11-22       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.